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Comparison of the Vitek 2, MicroScan, and Etest Methods with the
Agar Dilution Method in Assessing Colistin Susceptibility of
Bloodstream Isolates of Acinetobacter Species from a Korean
University Hospital
Seung Yeob Lee,a Jong Hee Shin,a Kyungwon Lee,b Min Young Joo,a Kyung Hwa Park,c Myung Geun Shin,a Soon Pal Suh,a
Dong Wook Ryang,a Soo Hyun Kima
Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Republic of Koreaa; Department of Laboratory Medicine and Research
Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Republic of Koreab; Department of Internal Medicine, Chonnam National University Medical
School, Gwangju, Republic of Koreac
We evaluated three commercial colistin susceptibility testing methods using 213 bloodstream Acinetobacter isolates identified by
gene sequencing. Compared to the agar dilution reference method, excellent categorical agreements (both 99.1%) were observed
using Vitek 2 and Etest, compared to 87.3% (95.7% for Acinetobacter baumannii and 80.7% for non-baumannii Acinetobacter
isolates) usingMicroScan.
Acinetobacter species have emerged as important causativepathogens of a variety of nosocomial infections such as bac-
teremia, hospital-acquired pneumonia, and urinary tract infec-
tions (1). This organism commonly presents resistance to multi-
ple antimicrobial agents, including carbapenems (multidrug
resistance), except to an “old” drug, colistin (polymyxin E), which
often remains the only effective therapeutic option (2). However,
Acinetobacter strains developing resistance to colistin have re-
cently been described (3). Therefore, rapid and reliable methods
for colistin susceptibility testing of Acinetobacter species are
needed (4).
High error rates and low levels of reproducibility of the disk
diffusion method for detecting colistin resistance are well docu-
mented (4), but Etest has shown excellent agreement with agar
dilution (AD) and broth microdilution for testing colistin resis-
tance in major Gram-negative bacteria (4–6). However, the per-
formance of automated antimicrobial susceptibility testing sys-
tems has rarely been assessed in terms of determining colistin
susceptibility inAcinetobacter species, especially for non-bauman-
nii Acinetobacter strains (4, 7). In this study, by testing a broad
range of Acinetobacter species isolated from blood cultures at a
university hospital during a 4-year period, we evaluated the suit-
ability of three commercial methods for colistin susceptibility test-
ing—Vitek 2 (Vitek 2 XL; bioMérieux, Hazelwood, MO), Mi-
croScan (MicroScan WalkAway 96 Plus; Siemens Healthcare
Diagnostics Inc., Deerfield, IL), and Etest (Etest; bioMérieux SA,
Marcy l’Etoile, France)—in comparison with the AD reference
method.
A total of 213 nonduplicate bloodstream infection (BSI) iso-
lates of Acinetobacter species were obtained from patient blood
cultures at Chonnam National University Hospital (a 1,000-bed
tertiary care hospital in Gwangju, Republic of Korea) from Janu-
ary 2008 to December 2011. Isolates were identified by partial
rpoB gene sequencing (8). DNA extraction and sequencing were
performed as described previously (9). Colistin susceptibility test-
ing with the Etest (Colistin CO 256), Vitek 2 (Gram-negative sus-
ceptibility card AST-N132), and MicroScan (Gram-negative
breakpoint combo panel type 42) methods was performed accord-
ing to the manufacturers’ instructions. The AD method was per-
formed according to Clinical and Laboratory Standards Institute
(CLSI) guidelines (10, 11). Categorical results of each method
were analyzed on the basis of the CLSI breakpoint for colistin
(MIC of2 g/ml, susceptible [S], and MIC of4 g/ml, resis-
tant) (11). Categorical agreement (CA) was defined as the per-
centage of isolates classified into the same category by the AD
reference method, and very major error (VME) and major error
(ME) were defined as described previously (12).
Of all 213 Acinetobacter BSI isolates, 13 (6.1%) demonstrated
colistin resistance (MIC of4 g/ml) by the AD method, which
included 10 isolates of Acinetobacter genomic species 13BJ
(GS13BJ), two isolates of A. junii, and one isolate of A. nosoco-
mialis. Overall, 100% (94/94) isolates of A. baumannii were sus-
ceptible to colistin, while 10.9% (13/119) isolates of non-bauman-
nii Acinetobacter species were resistant. This finding supports
previous reports showing that resistance to colistin may be more
common in non-baumannii Acinetobacter isolates than in A. bau-
mannii (13). For all 213 isolates, excellent CA (both99%) with
AD was observed with Vitek 2 and Etest, but CA with AD using
MicroScan was 87.3% (Table 1).
To date, only two studies have investigated the performance of
Vitek 2 for colistin susceptibility testing using clinical isolates of
Acinetobacter species (4, 7). However, as only 2 of the 67 isolates in
these studies were colistin resistant, it is not possible to draw de-
finitive conclusions regarding the efficacy of the Vitek 2 system for
detection of colistin resistance in Acinetobacter species until more
resistant isolates are tested (4, 7). In this study, we tested 213 BSI
Received 14 February 2013 Returned for modification 13 March 2013
Accepted 19 March 2013
Published ahead of print 27 March 2013
Address correspondence to Soo Hyun Kim, alpinboy@chonnam.ac.kr.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.00427-13
1924 jcm.asm.org Journal of Clinical Microbiology p. 1924–1926 June 2013 Volume 51 Number 6
 o
n
 M
ay 21, 2014 by YO
NSEI UNIV M
ED LIBRARY
http://jcm.asm.org/
D
ow
nloaded from
 
TABLE 1 Distribution of colistin MICs as determined by the agar dilution reference method, Vitek 2, MicroScan, and Etest and categorical
agreement between results obtained by the agar dilution method and each of the other three methods for 213 Acinetobacter bloodstream isolates
Species (no. of
isolates) Test systema
No. of isolates with colistin MIC (g/ml):
No. (%) of isolates with
result:
% categorical
agreement
with the agar
dilution
method
% of category
errors
0.5 1 2 4 8 16 32 32 Susceptible Resistant
Very
major Major
A. baumannii (94) Agar dilution 28 49 17 0 0 0 0 0 94 (100) 0 (0)
Vitek 2 79 11 4 0 0 0 94 (100) 0 (0) 100 0 0
MicroScan 90 3 1 90 (95.7) 4 (4.3) 95.7 0 4.3
Etest 93 0 0 0 0 0 1 0 93 (98.9) 1 (1.1) 98.9 0 1.1
A. nosocomialis (67) Agar dilution 6 42 18 1 0 0 0 0 66 (98.5) 1 (1.5)
Vitek 2 40 16 11 0 0 0 67 (100) 0 (0) 98.5 1.5 0
MicroScan 52 13 2 52 (77.6) 15 (22.4) 79.1 0 20.9
Etest 64 2 0 0 0 0 1 0 66 (98.5) 1 (1.5) 100 0 0
A. pittii (12) Agar dilution 5 6 1 0 0 0 0 0 12 (100) 0 (0)
Vitek 2 12 0 0 0 0 0 12 (100) 0 (0) 100 0 0
MicroScan 12 0 0 12 (100) 0 (0) 100 0 0
Etest 11 0 0 0 0 0 1 0 11 (91.7) 1 (8.3) 91.7 0 8.3
Acinetobacter genomic
species 13BJ (10)
Agar dilution 0 0 0 0 1 2 3 4 0 (0) 10 (100)
Vitek 2 0 0 1 2 0 7 1 (10.0) 9 (90.0) 90.0 10.0 0
MicroScan 2 0 8 2 (20.0) 8 (80.0) 80.0 20.0 0
Etest 0 0 0 1 0 2 7 0 0 (0) 10 (100) 100 0 0
A. ursingii (7) Agar dilution 5 2 0 0 0 0 0 0 7 (100) 0 (0)
Vitek 2 7 0 0 0 0 0 7 (100) 0 (0) 100 0 0
MicroScan 7 0 0 7 (100) 0 (0) 100 0 0
Etest 7 0 0 0 0 0 0 0 7 (100) 0 (0) 100 0 0
A. soli (6) Agar dilution 0 4 2 0 0 0 0 0 6 (100) 0 (0)
Vitek 2 6 0 0 0 0 0 6 (100) 0 (0) 100 0 0
MicroScan 6 0 0 6 (100) 0 (0) 100 0 0
Etest 3 3 0 0 0 0 0 0 6 (100) 0 (0) 100 0 0
A. bereziniae (5) Agar dilution 0 2 3 0 0 0 0 0 5 (100) 0 (0)
Vitek 2 0 3 2 0 0 0 5 (100) 0 (0) 100 0 0
MicroScan 0 1 4 0 (0) 5 (100) 0 0 100
Etest 5 0 0 0 0 0 0 0 5 (100) 0 (0) 100 0 0
A. junii (3) Agar dilution 0 1 0 0 1 1 0 0 1 (33.3) 2 (66.7)
Vitek 2 0 1 0 0 1 1 1 (33.3) 2 (66.7) 100 0 0
MicroScan 1 1 1 1 (33.3) 2 (66.7) 100 0 0
Etest 0 1 0 0 2 0 0 0 1 (33.3) 2 (66.7) 100 0 0
A. johnsonii (1) Agar dilution 1 0 0 0 0 0 0 0 1 (100) 0 (0)
Vitek 2 1 0 0 0 0 0 1 (100) 0 (0) 100 0 0
MicroScan 1 0 0 1 (100) 0 (0) 100 0 0
Etest 0 1 0 0 0 0 0 0 1 (100) 0 (0) 100 0 0
Other Acinetobacter
species (8)
Agar dilution 0 3 5 0 0 0 0 0 8 (100) 0 (0)
Vitek 2 4 2 2 0 0 0 8 (100) 0 (0) 100 0 0
MicroScan 6 1 1 6 (75.0) 2 (25.0) 75.0 0 25.0
Etest 8 0 0 0 0 0 0 0 8 (100) 0 (0) 100 0 0
Total (213) Agar dilution 45 109 46 1 2 3 3 4 200 (93.9) 13 (6.1)
Vitek 2 149 33 20 2 1 8 202 (94.8) 11 (5.2) 99.1 0.9 0
MicroScan 177 19 17 177 (83.1) 36 (16.9) 87.3 0.9 11.7
Etest 191 7 0 1 2 2 10 0 198 (93.0) 15 (7.0) 99.1 0 0.9
a The colistin MIC ranges tested were0.5 to32 g/ml by the agar dilution method. The colistin MIC ranges determined by Vitek 2 were0.5 to16 g/ml, and MICs of16
g/ml determined by Vitek 2 were presented as 16 g/ml. The colistin MIC ranges determined by MicroScan were2 to4 g/ml, and MICs of2 and4 g/ml determined by
MicroScan were presented as 2 and 8 g/ml, respectively. Etest MICs were rounded up to the next 2-fold dilution value.
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isolates, including 13 isolates of colistin-resistant Acinetobacter
species. Vitek 2 showed excellent CA with 0.9% VMEs and no ME.
Etest also showed excellent CA with AD for both A. baumannii
(98.9%) and non-baumannii Acinetobacter species (99.2%). Al-
though colistin Etest gives high error rates for cystic fibrosis iso-
lates of Pseudomonas aeruginosa and Stenotrophomonas malto-
philia (14), our data showed no VME and only 0.9% MEs of the
colistin Etest for Acinetobacter species, results which are in agree-
ment with other reports (4, 7).
The performance of MicroScan for colistin susceptibility test-
ing has not been reported. In our study, the CA with AD for Mi-
croScan was 95.7% for A. baumannii but 80.7% for non-bauman-
nii Acinetobacter isolates. MicroScan produced VMEs in two
isolates ofAcinetobacterGS13BJ and MEs in 25 isolates, composed
of 4.3% (4/94) A. baumannii and 17.6% (21/119) non-baumannii
Acinetobacter species, suggesting that non-baumannii Acinetobac-
ter species rather than A. baumannii were the main source of er-
rors. Reasons for the low CA with MicroScan are unknown. How-
ever, MicroScan generated the narrowest distribution of colistin
MICs (2 to 4 g/ml), compared with Etest (0.016 to 256 g/
ml) or Vitek 2 (0.5 to16g/ml). Considering the CLSI break-
point for colistin (susceptible [S],2g/ml; resistant 4g/ml),
the presence of only three point (2, 4, and4 g/ml) determi-
nations of colistin MICs in the MicroScan system appears to create
difficulty in differentiating colistin-resistant from -susceptible
Acinetobacter isolates.
The limitation of our study is that no colistin-resistant A. bau-
mannii isolates were tested. However, our study included 10 iso-
lates of Acinetobacter GS13BJ, which has consistently been re-
ported to be resistant to colistin (1, 13, 15). In the present study, of
10 Acinetobacter GS13BJ isolates, 10 (100%), 9 (90%), 8 (80%),
and 10 (100%) had a colistin MIC of 4 g/ml by AD, Vitek 2,
MicroScan, and Etest, respectively. These data suggest that Acin-
etobacter GS13BJ is innately resistant to colistin and that the AD
and Etest, followed by Vitek 2, have the best ability to detect colis-
tin resistance in this species.
In conclusion, our findings indicate, for the first time, that the
MicroScan is unsuitable for colistin susceptibility testing of Acin-
etobacter species, especially non-baumannii Acinetobacter species,
due to its low reliability; in contrast, Etest and Vitek 2 are useful
methods for discrimination of colistin-resistant and -susceptible
Acinetobacter isolates.
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